Advertisement
ENLV vs VBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENLV is a StrongBuy and VBIO is a StrongBuy.
ENLV's RSI Oscillator is sitting in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENLV entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.001) is normal, around the industry mean (2.973). P/E Ratio (0.000) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VBIO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for VBIO turned positive on September 29, 2026. Looking at past instances where VBIO's MACD turned positive, the stock continued to rise in 36 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +39.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where VBIO advanced for three days, in 167 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
VBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VBIO as a result. In 89 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VBIO entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.200) is normal, around the industry mean (2.973). P/E Ratio (-0.005) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.510) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. VBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ENLV | VBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 1 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 99 | |
SMR RATING 1..100 | 11 | 100 | |
PRICE GROWTH RATING 1..100 | 98 | 98 | |
P/E GROWTH RATING 1..100 | 97 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ENLV's Valuation (49) in the Medical Specialties industry is in the same range as VBIO (67) in the null industry. This means that ENLV’s stock grew similarly to VBIO’s over the last 12 months.
VBIO's Profit vs Risk Rating (99) in the null industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that VBIO’s stock grew similarly to ENLV’s over the last 12 months.
ENLV's SMR Rating (11) in the Medical Specialties industry is significantly better than the same rating for VBIO (100) in the null industry. This means that ENLV’s stock grew significantly faster than VBIO’s over the last 12 months.
ENLV's Price Growth Rating (98) in the Medical Specialties industry is in the same range as VBIO (98) in the null industry. This means that ENLV’s stock grew similarly to VBIO’s over the last 12 months.
ENLV's P/E Growth Rating (97) in the Medical Specialties industry is in the same range as VBIO (98) in the null industry. This means that ENLV’s stock grew similarly to VBIO’s over the last 12 months.
| ENLV | VBIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | N/A |
| Stochastic ODDS (%) | N/A | 1 day ago 85% |
| Momentum ODDS (%) | N/A | 1 day ago 90% |
| MACD ODDS (%) | N/A | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 79% | 29 days ago 85% |
| Declines ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| BollingerBands ODDS (%) | N/A | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENLV’s FA Score shows that 1 FA rating(s) are green while VBIO’s FA Score has 0 green FA rating(s).
- ENLV’s FA Score: 1 green, 4 red.
- VBIO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENLV’s TA Score shows that 2 TA indicator(s) are bullish while VBIO’s TA Score has 4 bullish TA indicator(s).
- ENLV’s TA Score: 2 bullish, 2 bearish.
- VBIO’s TA Score: 4 bullish, 3 bearish.
Price Growth
ENLV (@Biotechnology) experienced а -11.15% price change this week, while VBIO (@Biotechnology) price change was -22.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
ENLV is expected to report earnings on Nov 13, 2026.
VBIO is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ENLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with APVO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then APVO could also see price increases.
| Ticker / NAME | Correlation To ENLV | 1D Price Change % | ||
|---|---|---|---|---|
| ENLV | 100% | -1.48% | ||
| APVO - ENLV | 39% Loosely correlated | +0.62% | ||
| CAPR - ENLV | 38% Loosely correlated | +4.25% | ||
| AXON - ENLV | 29% Poorly correlated | +2.98% | ||
| AMRN - ENLV | 29% Poorly correlated | +0.78% | ||
| CRBU - ENLV | 29% Poorly correlated | +2.87% | ||
More | ||||
VBIO and
Correlation & Price change
A.I.dvisor tells us that VBIO and DARE have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VBIO and DARE's prices will move in lockstep.
| Ticker / NAME | Correlation To VBIO | 1D Price Change % | ||
|---|---|---|---|---|
| VBIO | 100% | -14.63% | ||
| DARE - VBIO | 25% Poorly correlated | -5.28% | ||
| SNGX - VBIO | 25% Poorly correlated | +0.30% | ||
| BMEA - VBIO | 23% Poorly correlated | -15.23% | ||
| ENLV - VBIO | 23% Poorly correlated | -1.48% | ||
| BNTC - VBIO | 23% Poorly correlated | +3.76% | ||
More | ||||